Loading...
Sign in to edit your profile (add interests, overview, photo, etc.)

    Park, Catherine

    TitleBiologist Faculty
    SchoolLawrence Berkeley National Lab
    DepartmentBiological Systems & Eng
    Address1 Cyclotron Road
    Berkeley CA 94720
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park C. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. PMID: 26860947; PMCID: PMC4767608 [Available on 02/09/17].
      2. Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park C, Suh WW, Toppmeyer D, Zook J, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. Oncology (Williston Park). 2015 Jun; 29(6):446-58, 460-1. PMID: 26089220.
        View in: PubMed
      3. Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park C, Coussens LM. TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res. 2015 May; 3(5):518-25. PMID: 25716473; PMCID: PMC4420686.
      4. Halyard MY, Harris EE, Bailey L, Bellon JR, Freedman GM, Goyal S, Horst KC, Moran MS, Park C, Suh WW, Toppmeyer D, Haffty BG. ACR Appropriateness Criteria local-regional recurrence (LRR) and salvage surgery-breast cancer. Oncology (Williston Park). 2014 Feb; 28(2):157-64, C3. PMID: 24701707.
        View in: PubMed
      5. Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park C, Weidhaas JB, Zietman AL, Steinberg M. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):11-7. PMID: 24246724.
        View in: PubMed
      6. Alvarado MD, Mohan AJ, Esserman LJ, Park C, Harrison BL, Howe RJ, Thorsen C, Ozanne EM. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013 Sep; 20(9):2873-80. PMID: 23812769.
        View in: PubMed
      7. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park C, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969. PMID: 23667451; PMCID: PMC3646993.
      8. Carbonell WS, DeLay M, Jahangiri A, Park C, Aghi MK. ß1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013 May 15; 73(10):3145-54. PMID: 23644530; PMCID: PMC4040366.
      9. Ahmed KM, Zhang H, Park C. NF-?B regulates radioresistance mediated by ß1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 2013 Jun 15; 73(12):3737-48. PMID: 23576567; PMCID: PMC3698967.
      10. Park C, Georgescu W, Polyzos A, Pham C, Ahmed KM, Zhang H, Costes SV. Rapid and automated multidimensional fluorescence microscopy profiling of 3D human breast cultures. Integr Biol (Camb). 2013 Apr; 5(4):681-91. PMID: 23407655; PMCID: PMC3641787.
      11. Nam JM, Ahmed KM, Costes S, Zhang H, Onodera Y, Olshen AB, Hatanaka KC, Kinoshita R, Ishikawa M, Sabe H, Shirato H, Park C. ß1-Integrin via NF-?B signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer. Breast Cancer Res. 2013; 15(4):R60. PMID: 23883667; PMCID: PMC3978561.
      12. Peled AW, Foster RD, Esserman LJ, Park C, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012 Sep; 130(3):503-9. PMID: 22929235.
        View in: PubMed
      13. Huang C, Park C, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. ß1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84. PMID: 21884573; PMCID: PMC3236347.
      14. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park C. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr; 3(4):490-6. PMID: 21416100; PMCID: PMC3698966.
      15. Nam JM, Onodera Y, Bissell MJ, Park C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010 Jul 01; 70(13):5238-48. PMID: 20516121; PMCID: PMC2933183.
      16. Park C, Yom SS, Podgorsak MB, Harris E, Price RA, Bevan A, Pouliot J, Konski AA, Wallner PE. American Society for Therapeutic Radiology and Oncology (ASTRO) Emerging Technology Committee report on electronic brachytherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):963-72. PMID: 20206016.
        View in: PubMed
      17. Nam JM, Chung Y, Hsu HC, Park C. beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol. 2009 Nov; 85(11):923-8. PMID: 19895268.
        View in: PubMed
      18. Weigelt B, Lo AT, Park C, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010 Jul; 122(1):35-43. PMID: 19701706; PMCID: PMC2935800.
      19. Park C, Rembert J, Chew K, Moore D, Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):75-9. PMID: 18692323.
        View in: PubMed
      20. Park CC, Zhang HJ, Yao ES, Park C, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008 Jun 01; 68(11):4398-405. PMID: 18519702; PMCID: PMC3719863.
      21. Cordes N, Park C. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol. 2007 Nov-Dec; 83(11-12):753-60. PMID: 18058364.
        View in: PubMed
      22. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park C, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006 Feb 01; 66(3):1526-35. PMID: 16452209; PMCID: PMC2933188.
      23. Park C, Henshall-Powell RL, Erickson AC, Talhouk R, Parvin B, Bissell MJ, Barcellos-Hoff MH. Ionizing radiation induces heritable disruption of epithelial cell interactions. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10728-33. PMID: 12960393; PMCID: PMC196872.

      A U.S. Department of Energy National Laboratory Managed by the University of California

      This site is running Profiles RNS version v2.10.1-414-g6fb82b0a.